Supplemental material
Open access
1,665
Views
0
CrossRef citations to date
0
Altmetric
Drug Evaluation
Sulbactam–durlobactam: a β-lactam/β-lactamase inhibitor combination targeting Acinetobacter baumannii
Sarah M McLeod1 Innoviva Specialty Therapeutics, Inc., an affiliate of Entasis Therapeutics Inc., 35 Gatehouse Drive, Waltham, MA 02451, USAhttps://orcid.org/0009-0003-7827-794X
, John P O'Donnell1 Innoviva Specialty Therapeutics, Inc., an affiliate of Entasis Therapeutics Inc., 35 Gatehouse Drive, Waltham, MA 02451, USAhttps://orcid.org/0000-0001-5502-8738
, Navaneeth Narayanan2 Rutgers University Ernest Mario School of Pharmacy, Department of Pharmacy Practice & Administration, Piscataway, NJ 08901, USAhttps://orcid.org/0000-0001-5071-9193
, John P Mills3 Division of Allergy, Immunology & Infectious Diseases, Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USAhttps://orcid.org/0000-0001-6529-2911
& Keith S Kaye3 Division of Allergy, Immunology & Infectious Diseases, Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USACorrespondence[email protected]
https://orcid.org/0000-0003-2051-1732
https://orcid.org/0000-0003-2051-1732
Pages 563-576
|
Received 08 Nov 2023, Accepted 02 Feb 2024, Published online: 01 Mar 2024
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.